Furazolium, an antibacterial agent, was studied for the management of skin infections. However, information about the current use of this drug is not available.

Evacetrapib (LY2484595) is a novel benzazepine-based CETP inhibitor that has been developed at Lilly Research Laboratories. Evacetrapib inhibits CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. Phase 3. On 01 Sep 2016 Eli Lilly terminates the phase III ACCENTUATE trial in Hyperlipidaemia (Adjunctive treatment) in USA and Puerto Rico (PO) due to insufficient efficacy (NCT02227784).

Eprovafen is an anti-inflammatory compound.

Eptaloprost is a novel concept PGI2-mimetic, which is designed to be activated to the pharmacologically potent cicaprost via beta-oxidation. Eptaloprost has a significant antimetastatic activity in a spontaneously metastasizing tumor model. Eptaloprost was undergoing phase I clinical trials with Schering AG in Germany for the treatment of cardiovascular disorders.

Nicofurate is a vasodilator, antilipidemic agent.

Napirimus is an immunosuppressant agent.

Nabazenil is a synthetic cannabinoid receptor agonist, which has anticonvulsant properties. Nabazenil was undergoing preclinical trials with HG Pars in the USA.

Ozolinone, an active metabolite of diuretic etozoline was studied also as a loop diuretic. Experiments on dogs have shown that ozolinone, induced stereoselective and prostaglandin-dependent renin secretion, which was involved in the regulation of intra-renal hemodynamics. Information about the current use of this drug is not available.

Taltobulin, also known as HTI-286 and SPA-110, is a fully synthetic analog of the natural tripeptide hemiasterlin, inhibits tubulin polymerization and circumvents transport-based resistance to taxanes. Taltobulin was a potent inhibitor of proliferation (mean IC50 = 4 nm in 18 human tumor cell lines) and had substantially less interaction with multidrug resistance protein (P-glycoprotein) than currently used antimicrotubule agents, including paclitaxel, docetaxel, vinorelbine, or vinblastine. Taltobulin showed strong antitumor activity both in androgen-dependent and androgen- independent tumors and may be a promising agent in second- line treatment strategies for patients suffering from docetaxel- refractory prostate cancer.

Bindarit (2-Methyl-2-[[1-(phenylmethyl)-1H-indazol-3yl]methoxy]propanoic acid; AF-2838) is an indazolic derivative that is devoid of any immunosuppressive effects and has no effect on arachidonic acid metabolism. It has been proved to have anti-inflammatory activity in a number of experimental diseases, including pancreatitis, arthritis, and lupus nephritis. This therapeutic effect has been associated with its ability to interfere selectively with monocyte recruitment, although the underlying molecular mechanisms are unknown. Bindarit selectively inhibits the production of the monocyte chemotactic protein subfamily of CC inflammatory chemokines (MCP-1/CCL2, MCP-3/CCL7, MCP-2/CCL8) without affecting the production of the cytokines IL-1, IL-6, or the chemokines IL-8, MIP-1α.